Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications

医学 双盲 去神经支配 导管 随机对照试验 盲法研究 麻醉 泌尿科 外科 内科学 病理 安慰剂 替代医学
作者
Felix Mahfoud,Michael A. Weber,Roland E. Schmieder,Melvin D. Lobo,Peter J. Blankestijn,Alexandre Persu,Tim A. Fischell,Helen Parise,Atul Pathak,David E. Kandzari
出处
期刊:American Heart Journal [Elsevier BV]
卷期号:239: 90-99 被引量:17
标识
DOI:10.1016/j.ahj.2021.05.015
摘要

Arterial hypertension is a common and life-threatening condition and poses a large global health burden. Device-based treatments have been developed as adjunctive or alternative therapy, to be used with or without antihypertensive medication for treating uncontrolled hypertension. The safety and feasibility of chemical renal denervation (RDN) using the Peregrine Catheter and alcohol were demonstrated in a first-in-man and open-label clinical trials, prompting the initiation of the ongoing TARGET BP OFF-MED and TARGET BP I trials. The TARGET BP trials are randomized, blinded, sham-controlled trials designed to assess the safety and efficacy of alcohol-mediated RDN for the treatment of uncontrolled hypertension in the absence of antihypertensive medications (TARGET BP OFF-MED) or in addition to prescribed antihypertensive medications (TARGET BP I). Subjects with confirmed uncontrolled hypertension and suitable renal artery anatomy are randomized (1:1) to receive either RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery) infused through the Peregrine Catheter or diagnostic renal angiography only (sham procedure). TARGET BP OFF-MED completed enrollment and randomized 96 subjects. TARGET BP I will randomize approximately 300 subjects and will transition to an open-label safety cohort of approximately 300 subjects receiving RDN once the primary efficacy endpoint of the Randomized Controlled Trial (RCT) cohort has been met. Primary endpoints are change in mean 24-hour ambulatory systolic blood pressure from baseline to 8 weeks (TARGET BP OFF-MED) and 3 months (TARGET BP I) post-procedure. The TARGET BP trials are the first large-scale, international, randomized trials aimed to investigate the safety and BP lowering efficacy of a novel RDN method, with perivascular alcohol delivery using the Peregrine Kit.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Huanghong发布了新的文献求助10
刚刚
鹿梦发布了新的文献求助10
刚刚
碧蓝万声发布了新的文献求助10
1秒前
花飞飞凡发布了新的文献求助10
1秒前
阿皮发布了新的文献求助30
2秒前
活菩萨完成签到,获得积分10
2秒前
Jilin发布了新的文献求助10
2秒前
2秒前
esbd完成签到,获得积分10
3秒前
DrW完成签到,获得积分0
3秒前
3秒前
孔雀翎完成签到,获得积分10
3秒前
大风发布了新的文献求助10
4秒前
汉堡包应助meixinmeifei采纳,获得10
5秒前
5秒前
5秒前
啦啦啦发布了新的文献求助10
5秒前
青禾向暖完成签到,获得积分10
6秒前
6秒前
moonlight完成签到,获得积分10
6秒前
6秒前
孤独炳完成签到,获得积分10
7秒前
7秒前
SABUBU完成签到,获得积分10
7秒前
JamesPei应助安静的画笔采纳,获得10
7秒前
科研通AI6.2应助michaelzy采纳,获得30
7秒前
雪落长安里完成签到,获得积分10
8秒前
Jasper应助森屿海港采纳,获得10
8秒前
徐菁完成签到,获得积分10
9秒前
晨儿发布了新的文献求助10
9秒前
Vater发布了新的文献求助10
9秒前
大模型应助lkk采纳,获得10
9秒前
10秒前
汉堡包应助鹿梦采纳,获得10
10秒前
10秒前
10秒前
无私的亦巧完成签到,获得积分10
10秒前
10秒前
11秒前
zjzj发布了新的文献求助10
11秒前
高分求助中
Adhesion Science: Principles & Practice 1234
Signals, Systems, and Signal Processing 610
Introduction to Cosmetic Formulation and Technology, 2nd Edition 400
Petrology and Plate Tectonics,2025 400
Burger's Medicinal Chemistry and Drug Discovery 400
Programming for Chemical Engineers Using C, C++, and MATLAB 320
Birth of Twins After Genome Editing for HIV Resistance 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6690553
求助须知:如何正确求助?哪些是违规求助? 8433948
关于积分的说明 18019474
捐赠科研通 5917455
什么是DOI,文献DOI怎么找? 2984726
邀请新用户注册赠送积分活动 1960695
关于科研通互助平台的介绍 1899421